Clinical Trials Browser

Terminated × Has results × Injections × Clear all

NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Phase 1/2 Terminated

12 enrolled 15 charts

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04081688 2026-02-05

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Phase 1 Terminated

16 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Triple Negative Breast Neoplasms

NCT05047536 2025-12-19

KZR-261 in Subjects With Advanced Solid Malignancies

Phase 1 Terminated

61 enrolled 25 charts

DermatologicGastrointestinalOther solid neoplasmThoracic

Uveal Melanoma, Melanoma, Mesothelioma, Neoplasm Metastasis, Colorectal Neoplasms

NCT05109442 2025-08-20

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Phase 1/2 Terminated

112 enrolled 28 charts

Other solid neoplasm

Advanced Solid Tumor

NCT02751528 2025-01-13

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Phase 1 Terminated

3 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Breast Neoplasms, Male

NCT04526288 2024-05-23

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Phase 2 Terminated

1 enrolled 6 charts

Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT04793399 2024-03-19

Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients

Phase 1/2 Terminated

9 enrolled 7 charts

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT00089284 2019-08-14

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Phase 1/2 Terminated

30 enrolled 12 charts

Lymphoma, Non-Hodgkin